Citius Pharmaceuticals Inc. Common - CTXR STOCK NEWS

Citius Pharmaceuticals (Nasdaq: CTXR) will present at two investor conferences in March 2022. Leonard Mazur, Executive Chairman, will discuss recent developments and future milestones. The conferences include the 34^th Annual ROTH Conference (March 13-15 at Ritz-Carlton, Laguna Niguel, California) and Maxim's 2022 Virtual Growth Conference (March 28-30, virtual). Participants can view on-demand presentations and schedule 1-on-1 meetings.

Citius focuses on oncology, anti-infectives, and stem cell therapies, with products like Mino-Lok® and I/ONTAK in late-stage trials.

Citius Pharmaceuticals (CTXR) announced the FDA's acceptance of its Investigational New Drug (IND) application for Halo-Lido, a treatment for hemorrhoids. This proprietary formulation combines halobetasol and lidocaine, aiming to alleviate painful symptoms associated with hemorrhoids, which affect over 10 million individuals annually in the U.S. The company plans to initiate a Phase 2b clinical trial in 2022, involving 300 participants to assess the efficacy of Halo-Lido. This development marks a significant step toward providing relief for patients suffering from hemorrhoidal disease.

Citius Pharmaceuticals (CTXR) reported its fiscal Q1 2022 results on February 10, 2022. The company had cash and equivalents of $65.4 million and a net loss of $9.2 million (or ($0.06) per share). R&D expenses decreased to $5.5 million, while G&A expenses rose to $2.9 million. Key developments include the completion of the Phase 3 trial for I/ONTAK, with topline results expected in H1 2022. New executives have been added to strengthen regulatory and clinical capabilities, supporting the late-stage pipeline.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced its participation in two virtual conferences in January 2022. Presentations will be accessible on-demand beginning January 10, 2022. The events include the H.C. Wainwright BioConnect Conference from January 10-13 and Biotech Showcase™ 2022 on January 10-12 and 17-19. Archived webcasts will be available for 90 days on the Citius website. The company focuses on critical care products, including Mino-Lok® and I/ONTAK, both in late-stage development. For more details, visit www.citiuspharma.com.

Citius Pharmaceuticals (Nasdaq: CTXR) reported its fiscal year 2021 results, highlighting significant advancements and financial activities. The company completed the subject treatment in the pivotal Phase 3 trial of I/ONTAK and expects topline results in the first half of 2022, with a BLA submission set for the second half. They raised $120.6 million in financing, boosting cash reserves to $70.1 million. However, the net loss increased to $23.1 million, primarily due to rising R&D and G&A expenses. Citius is positioned for growth with a robust pipeline and anticipates multiple milestones in 2022.

Citius Pharmaceuticals, Inc. (CTXR) has completed patient enrollment in its pivotal Phase 3 trial for I/ONTAK, a treatment for recurrent cutaneous T-cell lymphoma (CTCL). With 70 patients enrolled, the study aims to evaluate the drug's efficacy and safety, with topline results expected in H1 2022. The biologics license application (BLA) is anticipated in H2 2022. I/ONTAK, a reformulation of the previously approved ONTAK, targets IL-2 receptors and has received orphan drug designation from the FDA. This marks a significant step in expanding treatment options for advanced CTCL patients.

Citius Pharmaceuticals, Inc. (CTXR) announced the appointment of Kelly Creighton, PhD, as Executive Vice President of Chemistry, Manufacturing and Controls. Dr. Creighton brings nearly two decades of pharmaceutical industry expertise, with over 50 investigational new drug submissions and 20 approved applications. He will oversee global regulatory and manufacturing strategies for Citius's five pipeline programs, as the company prepares for commercial success with two late Phase 3 trials nearing completion. Management expresses confidence in his ability to drive the company’s clinical development and regulatory pathways forward.

Citius Pharmaceuticals (Nasdaq: CTXR) announced a KOL webinar on November 11, 2021, at 11:30 AM ET addressing the salvage of central venous catheters in patients with CLABSI. Leading experts Issam Raad from MD Anderson and Mark Rupp from the University of Nebraska will discuss the unmet medical needs and the impact of COVID-19 on infection rates. Citius's Chief Medical Officer, Myron Czuczman, will provide updates on Mino-Lok®, their antibiotic treatment for catheter-related infections, currently in a Phase 3 clinical trial. Pre-registration is required for participation.

Citius Pharmaceuticals (Nasdaq: CTXR) will host a webcast on October 20, 2021, at 8:30 a.m. ET, to discuss its acquisition of I/ONTAK (E7777), an enhanced formulation of the immunotoxin ONTAK, previously FDA-approved for cutaneous T-cell lymphoma (CTCL). CEO Myron Holubiak and other executives will outline the company's strategy and the potential of I/ONTAK, which has received regulatory approval in Japan and orphan drug designation from the FDA. A pivotal study on I/ONTAK is underway, with results expected in mid-2022.